Status:
COMPLETED
Safety and Efficacy of Bepotastine Besilate Ophthalmic Solution in Seasonal Allergic Conjunctivitis Patients
Lead Sponsor:
Bausch & Lomb Incorporated
Conditions:
Allergic Conjunctivitis
Eligibility:
All Genders
12+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to study the safety and efficacy of bepotastine besilate ophthalmic solution in allergic conjunctivitis patients.
Eligibility Criteria
Inclusion
- Subjects 12 years of age and older with 2-year history of allergic conjunctivitis
Exclusion
- No active ocular or nasal infection
Key Trial Info
Start Date :
June 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2010
Estimated Enrollment :
245 Patients enrolled
Trial Details
Trial ID
NCT01174823
Start Date
June 1 2010
End Date
December 1 2010
Last Update
September 14 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
ISTA Pharmaceuticals, Inc.
Irvine, California, United States, 92618